Association between Emphysema and Chronic Obstructive Pulmonary Disease Outcomes in the COPDGene and SPIROMICS Cohorts: A Post Hoc Analysis of Two Clinical Trials.

The use of thoracic computed tomographic (CT) imaging in current and former smokers is becoming increasingly more common because of its widespread availability and utility in lung cancer screening. Prior studies have demonstrated associations between CT measures of emphysema and respiratory symptoms, exacerbations, and mortality (1–5). However, thus far, practical guidance on how to incorporate increasingly available quantitative imaging data into clinical practice is lacking. In this analysis, we use data from two large NIH-sponsored cohort studies, SPIROMICS (Subpopulations and Intermediate Outcomes in COPD Study) and COPDGene (COPD Genetic Epidemiology), to examine the relationship between a readily available metric, CT-based emphysema, and risk for important patient outcomes including symptoms, exacerbations, and mortality. The goal of our analysis is not to advocate for routine CT imaging in chronic obstructive pulmonary disease (COPD) but, rather, to provide clinicians with guidance on how to translate increasingly available quantitative imaging data into information that can guide patient decision-making. We used data from COPDGene and SPIROMICS, both NIH-funded multicenter cohort studies of smokers with and without airflow obstruction. All subjects were age 40–80 years with 10 pack-years or more of exposure (6, 7). Exacerbations were defined by use of an antibiotic and/or steroid, emergency room visit, or hospital admission for a respiratory “flare-up” on the American Thoracic Society Respiratory Disease questionnaire. Exacerbation data for both cohorts were captured via longitudinal follow-up protocols. For both studies, all participants underwent spirometry before and after the administration of a short-acting bronchodilator; postbronchodilator values were used in this analysis. We analyzed lung parenchyma on volumetric CT scans of the chest obtained at full inspiration, using VIDA software (VIDA Diagnostics), with percentage emphysema defined by the percentage of voxels less than 2950 Hounsfield units (7, 8). Statistical analyses were performed in R version 3.1. 3 (www.r-project.org). Analyses were performed first in the COPDGene cohort, with validation conducted using the SPIROMICS cohort. Plots for average event rates were created using raw averages for event rates grouped by nearest emphysema percentile. Overlaid are age-adjusted event rates by emphysema percentile, estimated using linear splines. Visual inspection of plots suggested 5% emphysema as a significant threshold for several clinically important metrics. The threshold of 5% is also roughly the 90th percentile value of emphysema for normal individuals within the COPDGene cohort (9). P value for average follow-up was based on restricted mean test. The statistical analysis of event rates (exacerbation rates and death) were conducted using quasiPoisson regression models unadjusted and adjusted for age. We created plots of emphysema versus relevant outcomes in COPD. In Figure 1, we examine mean prospective moderate and severe exacerbations in linear splines (black) and smoothed splines (red). A distinct increase in exacerbation frequency appears to occur roughly at 5% of emphysema. We saw similar findings for mean severe exacerbations (data not shown). In Figure 2, we compare emphysema percentage against average death rates in COPDGene and SPIROMICS. Again, a linear, positive association between increasing emphysema and deaths also appears at roughly 5% emphysema. Similar associations were seen with increases in St. George’s Respiratory Questionnaire beginning at approximately 5% emphysema (data not shown). To confirm the visual findings, we split the cohort into individuals above and below a 5% emphysema threshold. In COPDGene, 5,366 subjects had less than 5% emphysema (72% with FEV1/FVC> 0.7 and 28% with FEV1/FVC> 0.7) versus 2,601 with 5% or more emphysema (17% with FEV1/FVC> 0.7 and 83% with FEV1/FVC> 0.7). A similar breakdown was seen in SPIROMICS. The 5% or more emphysema threshold was significantly associated with greater risk and St. George’s Respiratory Questionnaire score (35.1 vs. 22.4; P, 0.001) in COPDGene and SPIROMICS (39.6 vs. 27.1; P, 0.001). We also found significantly higher mean exacerbation frequency in those with 5% or more emphysema (0.69 vs. 0.29 exacerbations/yr; P = 0.03) in COPDGene and SPIROMICS (0.46 vs. 0.21 exacerbations/yr; P, 0.001). The 5% or more emphysema threshold was also associated with greater mortality (3.18 vs. 0.98 deaths per 100 person-years; P, 0.001) compared with those with emphysema ,5% in COPDGene, as well as SPIROMICS (2.66 vs. 0.89 deaths per 100 person-years; P = 0.01). Additional analyses, however, stratified by presence of airflow obstruction, demonstrated that these relationships were maintained in those with airflow obstruction, but not in those without. We also noted that in COPDGene, of the individuals with 5% or more emphysema and FEV1/FVC, 0.70, 26% had no prior diagnosis of COPD. In SPIROMICS, of 994 individuals with 5% or more emphysema and FEV1/FVC, 0.70, 15% similarly had no prior diagnosis of COPD. Furthermore, among these participants meeting criteria for FEV1/FVC, 0.70 and 5% or more emphysema, 33.9% COPDGene is supported by NHLBI grants R01 HL089897 and R01 HL089856. The COPDGene project is also supported by the COPD Foundation through contributions made to an industry advisory board consisting of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion. SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C), which were supplemented by contributions made through the Foundation for the NIH from AstraZeneca; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; Forest Research Institute, Inc.; GSK; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Co.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi. M.K. H. , F.J.M. , B.D. R. , C.J.G. , and G.C. are supported by NHLBI grant R01 HL122438. M.K. H. is also supported by NHLBI grant K24 HL138118.